Mayo Clinic Q&A: FDA Sets Stricter Standards for COVID-19 Vaccine Development

Everyone
  • 1 video | 18m 29s
Rating 4.5 of 8 users Rating 4.5 of 8 users (8)
In an effort to reassure the public about the safety and effectiveness of a vaccine, the Food and Drug Administration has set stricter standards for COVID-19 vaccine development. These standards include following phase 3 clinical trial participants for at least two months, and having at least five severe COVID-19 cases in the placebo group. The agency's requirements are designed to ensure that there is adequate safety data on any vaccine before it is authorized for emergency use. (Published 10/14/2020)

YOU MIGHT ALSO LIKE

Rating 4.6 of 37 users Rating 4.6 of 37 users (37)
Rating 4.6 of 30 users Rating 4.6 of 30 users (30)
Rating 4.6 of 37 users Rating 4.6 of 37 users (37)